{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:01:44Z","timestamp":1768255304870,"version":"3.49.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03432-z","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:02:02Z","timestamp":1755504122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["T cell redirecting therapy for relapsed multiple myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"Melinda S. Y.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer","family":"Hellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"3432_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7.","journal-title":"Leukemia"},{"key":"3432_CR2","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, et al. International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(24)00043-3.","journal-title":"Lancet Oncol"},{"key":"3432_CR3","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of Teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:7540\u20137540. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7540.","journal-title":"J Clin Oncol"},{"key":"3432_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, et al. Real-world analysis of Teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371. https:\/\/doi.org\/10.1038\/s41375-024-02154-5.","journal-title":"Leukemia"},{"key":"3432_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","volume":"14","author":"F Malard","year":"2024","unstructured":"Malard F, et al. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 2024;14:219. https:\/\/doi.org\/10.1038\/s41408-024-01200-w.","journal-title":"Blood Cancer J"},{"key":"3432_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2024-206003","volume":"144","author":"MS Raab","year":"2024","unstructured":"Raab MS, et al. Phase 2 study of Teclistamab-Based induction regimens in patients with Transplant-Eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood. 2024;144:493\u2013493. https:\/\/doi.org\/10.1182\/blood-2024-206003.","journal-title":"Blood"},{"key":"3432_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0167-4781(01)00197-x","volume":"1518","author":"H Br\u00e4uner-Osborne","year":"2001","unstructured":"Br\u00e4uner-Osborne H, et al. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001;1518:237\u201348. https:\/\/doi.org\/10.1016\/s0167-4781(01)00197-x.","journal-title":"Biochim Biophys Acta"},{"key":"3432_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004;122:565\u201373. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x.","journal-title":"J Invest Dermatol"},{"key":"3432_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135:1232\u201343. https:\/\/doi.org\/10.1182\/blood.2019003342.","journal-title":"Blood"},{"key":"3432_CR10","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.Mct-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, et al. Anti-GPRC5D\/CD3 bispecific T-Cell-Redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18:1555\u201364. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-1216.","journal-title":"Mol Cancer Ther"},{"key":"3432_CR11","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody Talquetamab in multiple myeloma. Blood Adv. 2021;5:2196\u2013215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805.","journal-title":"Blood Adv"},{"key":"3432_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, et al. Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"key":"3432_CR13","doi-asserted-by":"publisher","first-page":"S561","DOI":"10.1016\/S2152-2650(24)01689-6","volume":"24","author":"L Rasche","year":"2024","unstructured":"Rasche L, et al. MM-492 Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24:S561\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3432_CR14","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1182\/blood-2024-211167","volume":"144","author":"M Janakiram","year":"2024","unstructured":"Janakiram M, et al. Real world evidence of outcomes of patients treated with Talquetamab in a heavily pretreated population with multiple myeloma with high exposure to prior BCMA Therapies- a report from the IMWG consortium. Blood. 2024;144:3368\u20133368. https:\/\/doi.org\/10.1182\/blood-2024-211167.","journal-title":"Blood"},{"key":"3432_CR15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025987","author":"J Eckmann","year":"2024","unstructured":"Eckmann J, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2\u2009+\u20091 format, for the treatment of multiple myeloma. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2024025987.","journal-title":"Blood"},{"key":"3432_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0002-9440(10)63276-2","volume":"165","author":"J Inoue","year":"2004","unstructured":"Inoue J, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol. 2004;165:71\u201381. https:\/\/doi.org\/10.1016\/s0002-9440(10)63276-2.","journal-title":"Am J Pathol"},{"key":"3432_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","volume":"18","author":"AG Polson","year":"2006","unstructured":"Polson AG, et al. Expression pattern of the human fcrh\/irta receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006;18:1363\u201373. https:\/\/doi.org\/10.1093\/intimm\/dxl069.","journal-title":"Int Immunol"},{"key":"3432_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s1074-7613(01)00109-1","volume":"14","author":"G Hatzivassiliou","year":"2001","unstructured":"Hatzivassiliou G, et al. IRTA1 and IRTA2, novel Immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14:277\u201389. https:\/\/doi.org\/10.1016\/s1074-7613(01)00109-1.","journal-title":"Immunity"},{"key":"3432_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","volume":"9","author":"AK Stewart","year":"2019","unstructured":"Stewart AK, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 2019;9:17. https:\/\/doi.org\/10.1038\/s41408-019-0178-8.","journal-title":"Blood Cancer J"},{"key":"3432_CR20","doi-asserted-by":"publisher","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","volume":"41","author":"S Kumar","year":"2023","unstructured":"Kumar S, et al. CAMMA 2: A phase I\/II trial evaluating the efficacy and safety of Cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. J Clin Oncol. 2023;41:TPS8064\u20138064. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8064.","journal-title":"J Clin Oncol"},{"key":"3432_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily Pre-Treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138:157\u2013157. https:\/\/doi.org\/10.1182\/blood-2021-147983.","journal-title":"Blood"},{"key":"3432_CR22","doi-asserted-by":"publisher","unstructured":"Jayaraman J, et al. CAR-T design: elements and their synergistic function. eBioMedicine. 2020;58. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"3432_CR23","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.biopha.2023.115691","volume":"168","author":"P Yuti","year":"2023","unstructured":"Yuti P, et al. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother. 2023;168:115691. https:\/\/doi.org\/10.1016\/j.biopha.2023.115691.","journal-title":"Biomed Pharmacother"},{"key":"3432_CR24","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, et al. Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022;13:947648. https:\/\/doi.org\/10.3389\/fimmu.2022.947648.","journal-title":"Front Immunol"},{"key":"3432_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"3432_CR26","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, et al. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8009\u20138009. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8009.","journal-title":"J Clin Oncol"},{"key":"3432_CR27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023;7:768\u201377. https:\/\/doi.org\/10.1182\/bloodadvances.2022007210.","journal-title":"Blood Adv"},{"key":"3432_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2024-198499","volume":"144","author":"CL 28 Freeman","year":"2024","unstructured":"28 Freeman CL, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial. Blood. 2024;144:1031\u20131031. https:\/\/doi.org\/10.1182\/blood-2024-198499.","journal-title":"Blood"},{"key":"3432_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17:23. https:\/\/doi.org\/10.1186\/s13045-024-01530-z.","journal-title":"J Hematol Oncol"},{"key":"3432_CR30","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/jco.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: Real-World experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397. https:\/\/doi.org\/10.1200\/jco.22.01365.","journal-title":"J Clin Oncol"},{"key":"3432_CR31","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, et al. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8012\u20138012. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8012.","journal-title":"J Clin Oncol"},{"key":"3432_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1182\/blood-2022-162469","volume":"140","author":"S Usmani","year":"2022","unstructured":"Usmani S, et al. KarMMa-2 cohort 2a: efficacy and safety of Idecabtagene vicleucel in clinical High-Risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140:875\u20137. https:\/\/doi.org\/10.1182\/blood-2022-162469.","journal-title":"Blood"},{"key":"3432_CR33","unstructured":"Xavier Leleu AC, Raje N, Mohan M, Benjamin R, Sperling A, Anderson LD, Dhodapkar M, Richard S, Kivovich V, Johnston S, Wu F, Basudhar D, Thompson E, Dhanda D, Eliason L, Tran S, Chaudhry M, Alsina M. In European Hematology Association 2024 Hybrid Congress; Jun 13\u201316, 2024, Madrid, ES., 2024."},{"key":"3432_CR34","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1182\/blood-2022-162615","volume":"140","author":"M Dhodapkar","year":"2022","unstructured":"Dhodapkar M, et al. KarMMa-2 cohort 2c: efficacy and safety of Idecabtagene vicleucel in patients with clinical High-Risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation. Blood. 2022;140:7441\u20133. https:\/\/doi.org\/10.1182\/blood-2022-162615.","journal-title":"Blood"},{"key":"3432_CR35","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2021-146074","volume":"138","author":"NWCJ Van de Donk","year":"2021","unstructured":"Van de Donk NWCJ, et al. CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel, a B-Cell maturation antigen (BCMA)-Directed chimeric antigen receptor T-Cell therapy, in patients with multiple myeloma and early relapse after initial therapy. Blood. 2021;138:2910\u20132910. https:\/\/doi.org\/10.1182\/blood-2021-146074.","journal-title":"Blood"},{"key":"3432_CR36","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144:2389\u2013401. https:\/\/doi.org\/10.1182\/blood.2024024582.","journal-title":"Blood"},{"key":"3432_CR37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"key":"3432_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, et al. Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"key":"3432_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, et al. GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"key":"3432_CR40","doi-asserted-by":"publisher","unstructured":"Jurgens EM, et al. Phase I trial of MCARH109, a G Protein-Coupled receptor class C group 5 member D (GPRC5D)-Targeted chimeric antigen receptor T-Cell therapy for multiple myeloma: an updated analysis. J Clin Oncol. 2024;JCO2401785. https:\/\/doi.org\/10.1200\/JCO-24-01785.","DOI":"10.1200\/JCO-24-01785"},{"key":"3432_CR41","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","volume":"42","author":"H Huang","year":"2024","unstructured":"Huang H, et al. OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed\/refractory multiple myeloma: long term follow-up results of phase 1 study (POLARIS). J Clin Oncol. 2024;42:7511\u20137511. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7511.","journal-title":"J Clin Oncol"},{"key":"3432_CR42","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, et al. Group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A Single-Arm, phase II trial. J Clin Oncol. 2023;41:2583\u201393. https:\/\/doi.org\/10.1200\/JCO.22.01824. Anti-G Protein-Coupled Receptor, Class C.","journal-title":"J Clin Oncol"},{"key":"3432_CR43","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD, Improving. CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","journal-title":"EBioMedicine"},{"key":"3432_CR44","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","volume":"7","author":"PC Johnson","year":"2023","unstructured":"Johnson PC, et al. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2023;7:3541\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2022009117.","journal-title":"Blood Adv"},{"key":"3432_CR45","doi-asserted-by":"publisher","first-page":"e432204","DOI":"10.1200\/edbk_432204","volume":"44","author":"M Mohan","year":"2024","unstructured":"Mohan M, Oekelen OV, Akhtar OS, Cohen A, Parekh S. Charting the course: sequencing immunotherapy for multiple myeloma. Am Soc Clin Oncol Educational Book. 2024;44:e432204. https:\/\/doi.org\/10.1200\/edbk_432204.","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"3432_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330. https:\/\/doi.org\/10.1182\/blood.2022015526.","journal-title":"Blood"},{"key":"3432_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117. https:\/\/doi.org\/10.1038\/s41408-023-00886-8.","journal-title":"Blood Cancer J"},{"key":"3432_CR48","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, et al. Efficacy and safety of Elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from magnetismm studies. J Clin Oncol. 2023;41:8008\u20138008. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8008.","journal-title":"J Clin Oncol"},{"key":"3432_CR49","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, et al. Efficacy and safety of Teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144:2375\u201388. https:\/\/doi.org\/10.1182\/blood.2023023616.","journal-title":"Blood"},{"key":"3432_CR50","doi-asserted-by":"publisher","unstructured":"Dima D et al. Safety and efficacy of Teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transpl Cell Ther. 2024;30:308 e301\u2013308 e313. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"3432_CR51","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","volume":"8","author":"KR Reyes","year":"2024","unstructured":"Reyes KR, et al. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024;8:2207\u201316. https:\/\/doi.org\/10.1182\/bloodadvances.2023012066.","journal-title":"Blood Adv"},{"key":"3432_CR52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354. https:\/\/doi.org\/10.1038\/s41375-024-02482-6.","journal-title":"Leukemia"},{"key":"3432_CR53","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107\u201316. https:\/\/doi.org\/10.1016\/S2352-3026(22)00372-6.","journal-title":"Lancet Haematol"},{"key":"3432_CR54","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","volume":"7","author":"MK Samur","year":"2023","unstructured":"Samur MK, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7:6599\u2013603. https:\/\/doi.org\/10.1182\/bloodadvances.2023010025.","journal-title":"Blood Adv"},{"key":"3432_CR55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5.","journal-title":"Nat Med"},{"key":"3432_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2019.04.008.","journal-title":"Leuk Res"},{"key":"3432_CR57","doi-asserted-by":"publisher","unstructured":"Scott SA et al. Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.04.002.","DOI":"10.1016\/j.clml.2025.04.002"},{"key":"3432_CR58","doi-asserted-by":"publisher","unstructured":"Yamamoto C et al. Cost-effectiveness of anti-BCMA chimeric antigen receptor t cell therapy in relapsed\/refractory multiple myeloma. Transplant Cell Ther. 2024;30:118 e111\u2013118 e115. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.001.","DOI":"10.1016\/j.jtct.2023.10.001"},{"key":"3432_CR59","doi-asserted-by":"publisher","first-page":"107327482211429","DOI":"10.1177\/10732748221142945","volume":"30","author":"KA Kapinos","year":"2023","unstructured":"Kapinos KA, Hu E, Trivedi J, Geethakumari PR, Kansagra A. Cost-Effectiveness analysis of CAR T-Cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma. Cancer Control. 2023;30:10732748221142945. https:\/\/doi.org\/10.1177\/10732748221142945.","journal-title":"Cancer Control"},{"key":"3432_CR60","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/jco.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312. https:\/\/doi.org\/10.1200\/jco.24.01008.","journal-title":"J Clin Oncol"},{"key":"3432_CR61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","volume":"23","author":"S Grosicki","year":"2023","unstructured":"Grosicki S, Bednarczyk M, Kociszewska K. Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther. 2023;23:775\u201382. https:\/\/doi.org\/10.1080\/14737140.2023.2236303.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3432_CR62","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","volume":"41","author":"HC Lee","year":"2023","unstructured":"Lee HC, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8006\u20138006. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8006.","journal-title":"J Clin Oncol"},{"key":"3432_CR63","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"3432_CR64","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"3432_CR65","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, et al. Pivotal phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036\u20138036. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036.","journal-title":"J Clin Oncol"},{"key":"3432_CR66","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1182\/blood-2023-179039","volume":"142","author":"D Sharon","year":"2023","unstructured":"Sharon D, et al. Bivalent BCMA binding and low affinity CD3 T-Cell engagement by Abbv-383 drives sustained activation with reduced T-Cell exhaustion in preclinical models of multiple myeloma. Blood. 2023;142:4666\u20134666. https:\/\/doi.org\/10.1182\/blood-2023-179039.","journal-title":"Blood"},{"key":"3432_CR67","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the international myeloma working group immunotherapy committee. Lancet Oncol. 2024;25:e374\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00094-9.","journal-title":"Lancet Oncol"},{"key":"3432_CR68","doi-asserted-by":"publisher","unstructured":"Banerjee R, et al. Early Time-to-Tocilizumab after B cell maturation antigen-Directed chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2021;27(477 e471\u2013477 e477). https:\/\/doi.org\/10.1016\/j.jtct.2021.03.004.","DOI":"10.1016\/j.jtct.2021.03.004"},{"key":"3432_CR69","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1080\/10428194.2023.2240920","volume":"64","author":"E Duvalyan","year":"2023","unstructured":"Duvalyan E, et al. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leuk Lymphoma. 2023;64:1888\u201391. https:\/\/doi.org\/10.1080\/10428194.2023.2240920.","journal-title":"Leuk Lymphoma"},{"key":"3432_CR70","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar AD, et al. Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry. Blood. 2024;144:4758\u20134758. https:\/\/doi.org\/10.1182\/blood-2024-201783.","journal-title":"Blood"},{"key":"3432_CR71","doi-asserted-by":"publisher","unstructured":"Hines MR et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29:438 e431-438 e416. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"3432_CR72","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer L, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38:372\u201382. https:\/\/doi.org\/10.1038\/s41375-023-02129-y.","journal-title":"Leukemia"},{"key":"3432_CR73","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjh.19515","volume":"205","author":"X Zhou","year":"2024","unstructured":"Zhou X, et al. Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: results from a prospective comprehensive biomarker study. Br J Haematol. 2024;205:999\u20131010. https:\/\/doi.org\/10.1111\/bjh.19515.","journal-title":"Br J Haematol"},{"key":"3432_CR74","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, et al. CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513. https:\/\/doi.org\/10.1182\/blood.2020010543.","journal-title":"Blood"},{"key":"3432_CR75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study. Blood Adv. 2023;7:555\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2022008042.","journal-title":"Blood Adv"},{"key":"3432_CR76","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, et al. Efficacy and safety of CD34\u2009+\u2009Stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transpl Cell Ther. 2023;29:567\u201371. https:\/\/doi.org\/10.1016\/j.jtct.2023.05.012.","journal-title":"Transpl Cell Ther"},{"key":"3432_CR77","doi-asserted-by":"publisher","first-page":"e7372","DOI":"10.1002\/cam4.7372","volume":"13","author":"J An","year":"2024","unstructured":"An J, et al. Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: risks and prevention strategies. Cancer Med. 2024;13:e7372. https:\/\/doi.org\/10.1002\/cam4.7372.","journal-title":"Cancer Med"},{"key":"3432_CR78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116. https:\/\/doi.org\/10.1038\/s41408-023-00879-7.","journal-title":"Blood Cancer J"},{"key":"3432_CR79","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2023.41.16_suppl.8020","volume":"41","author":"P Rodr\u00edguez-Otero","year":"2023","unstructured":"Rodr\u00edguez-Otero P, et al. Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with Talquetamab (tal) monotherapy in MonumenTAL-1. J Clin Oncol. 2023;41:8020\u20138020. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8020.","journal-title":"J Clin Oncol"},{"key":"3432_CR80","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14:158. https:\/\/doi.org\/10.1038\/s41408-024-01139-y.","journal-title":"Blood Cancer J"},{"key":"3432_CR81","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, et al. Immune effector cell-associated Enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:180. https:\/\/doi.org\/10.1038\/s41408-024-01167-8.","journal-title":"Blood Cancer J"},{"key":"3432_CR82","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1182\/blood-2024-199931","volume":"144","author":"ME Agha","year":"2024","unstructured":"Agha ME, et al. Systematic review of secondary primary malignancies (SPMs) in patients treated with chimeric antigen receptor T-Cell (CAR-T) therapies. Blood. 2024;144:7583\u20137583. https:\/\/doi.org\/10.1182\/blood-2024-199931.","journal-title":"Blood"},{"key":"3432_CR83","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","volume":"41","author":"AS Sperling","year":"2023","unstructured":"Sperling AS, et al. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM). J Clin Oncol. 2023;41:8004\u20138004. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8004.","journal-title":"J Clin Oncol"},{"key":"3432_CR84","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","volume":"12","author":"G Agliardi","year":"2025","unstructured":"Agliardi G, Dias J, Rampotas A, Garcia J, Roddie C. Accelerating and optimising CAR T-cell manufacture to deliver better patient products. Lancet Haematol. 2025;12:e57\u201367. https:\/\/doi.org\/10.1016\/S2352-3026(24)00273-4.","journal-title":"Lancet Haematol"},{"key":"3432_CR85","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15:3371. https:\/\/doi.org\/10.1038\/s41467-024-47801-8.","journal-title":"Nat Commun"},{"key":"3432_CR86","doi-asserted-by":"publisher","first-page":"832645","DOI":"10.3389\/fimmu.2022.832645","volume":"13","author":"LM Alabanza","year":"2022","unstructured":"Alabanza LM, et al. Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2. Front Immunol. 2022;13:832645. https:\/\/doi.org\/10.3389\/fimmu.2022.832645.","journal-title":"Front Immunol"},{"key":"3432_CR87","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","volume":"5","author":"L Carretero-Iglesia","year":"2024","unstructured":"Carretero-Iglesia L, et al. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer. 2024;5:1494\u2013514. https:\/\/doi.org\/10.1038\/s43018-024-00821-1.","journal-title":"Nat Cancer"},{"key":"3432_CR88","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/s1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, et al. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24:811\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(23)00246-2.","journal-title":"Lancet Oncol"},{"key":"3432_CR89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood.2024025231","volume":"145","author":"DG Coffey","year":"2025","unstructured":"Coffey DG, et al. Single-cell analysis of the multiple myeloma microenvironment after \u03b3-secretase Inhibition and CAR T-cell therapy. Blood. 2025;145:220\u201333. https:\/\/doi.org\/10.1182\/blood.2024025231.","journal-title":"Blood"},{"key":"3432_CR90","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"key":"3432_CR91","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, et al. Long-term survival and safety of Elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere. 2024;8:e136. https:\/\/doi.org\/10.1002\/hem3.136.","journal-title":"Hemasphere"},{"key":"3432_CR92","doi-asserted-by":"publisher","first-page":"10140","DOI":"10.1182\/blood-2022-159969","volume":"140","author":"N Bumma","year":"2022","unstructured":"Bumma N, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: A phase 1\/2 First-in-Human study. Blood. 2022;140:10140\u20131. https:\/\/doi.org\/10.1182\/blood-2022-159969.","journal-title":"Blood"},{"key":"3432_CR93","doi-asserted-by":"publisher","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","volume":"42","author":"CR Valdes","year":"2024","unstructured":"Valdes CR, et al. Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42:7531\u20137531. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7531.","journal-title":"J Clin Oncol"},{"key":"3432_CR94","doi-asserted-by":"publisher","unstructured":"Hillengass J et al. The Phase 2 cartitude-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1\u20133 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B). Transplant Cell Therapy. 2024;30:S36\u2013S37. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.054.","DOI":"10.1016\/j.jtct.2023.12.054."},{"key":"3432_CR95","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2024.42.16_suppl.7505","volume":"42","author":"B Arnulf","year":"2024","unstructured":"Arnulf B, et al. Efficacy and safety of ciltacabtagene autoleucel\u2009\u00b1\u2009lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. J Clin Oncol. 2024;42:7505\u20137505. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7505.","journal-title":"J Clin Oncol"},{"key":"3432_CR96","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal S, et al. BMS-986393 (CC-95266), a G Protein-Coupled receptor class C group 5 member D (GPRC5D)-Targeted chimeric antigen receptor (CAR) T-Cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study. Blood. 2023;142:219\u2013219. https:\/\/doi.org\/10.1182\/blood-2023-181857.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03432-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:41:07Z","timestamp":1757432467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03432-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03432-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DD declares consulting with personal payment from: Alexion, Apellis, Argenyx, BMS, Janssen, Regeneron, Roche-Genentech, Sanofi, Sorrento and Takeda. Clinical trial support to institution: K36 Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1573"}}